Articles published in Journal of Pharmacogenomics & Pharmacoproteomics have been cited by esteemed scholars and scientists all around the world. Journal of Pharmacogenomics & Pharmacoproteomics has got h-index 12, which means every article in Journal of Pharmacogenomics & Pharmacoproteomics has got 12 average citations.
Following are the list of articles that have cited the articles published in Journal of Pharmacogenomics & Pharmacoproteomics.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Year wise published articles |
30 | 30 | 13 | 4 | 7 |
Year wise citations received |
59 | 69 | 60 | 48 | 62 |
Journal total citations count | 548 |
Journal Impact Factor | 2.31 |
Journal 5 years Impact Factor | 3.74 |
Journal CiteScore | 4.86 |
Journal h-index | 12 |
Calpainopathy as differential diagnosis of idiopathic hyperCKemia
Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia
Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort
Mutation in the CAV3 gene causes partial caveolin-3 deficiency and persistent elevated levels of serum creatine kinase
Next-generation sequencing to diagnose muscular dystrophy, rhabdomyolysis, and hyperCKemia
Differential diagnosis of HyperCKemia
Interaction potential between clarithromycin and individual statins—A systematic review
Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions
An overview of statin-induced myopathy and perspectives for the future
Genomic variations affecting biological effects of statins
Polymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population
Clinical features related to statin?associated muscle symptoms
A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects
Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?
The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG)
Genetic and Clinical Factors Are Associated With Statin?Related Myotoxicity of Moderate Severity: A Case–Control Study
Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations
All for statins and statins for all; an update